This Eloxx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiated coverage: Neutral on RDW, Overweight on ELOX, Buys on SGHT and AU, and Market Perform on FFIN.
Stocks · News reference
Eloxx Pharmaceuticals Announces First Two Patients Dosed In Phase 2b EXACT Study Of Exaluren In Nonsense Mutation Alport Syndrome; Topline Data Expected Mid-2027
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Cantor Fitzgerald Initiates Coverage On Eloxx Pharma with Overweight Rating
Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Overweight rating.
Leerink Partners Initiates Coverage On Eloxx Pharma with Outperform Rating, Announces Price Target of $32
Leerink Partners analyst Joseph Schwartz initiates coverage on Eloxx Pharma (NASDAQ:ELOX) with a Outperform rating and announces Price Target of $32.